This prospective, observational study enrolled 150 adult patients with chronic myeloid leukaemia (CML) in chronic phase (CP) treated with nilotinib as second-line after imatinib, in a real life setting in France. Twothirds of patients switched to nilotinib treatment due to lack of imatinib efficacy. Of 146 evaluable patients, 16 (11Á0%) (95% confidence interval: 6Á4-17Á2%) achieved uMR 4
In the last decade, the landscape of chronic myeloid leukaemia (CML) management changed dramatically due to the advent of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 oncoprotein. Imatinib mesylate was the first TKI approved for newly diagnosed patients with CML. However, the results of the IRIS (International Randomized Study of Interferon and STI571) study (Druker et al, 2006) showed a 5-year resistance rate to imatinib of 14% and 4% of patients who discontinued therapy owing to an adverse event (AE). Imatinib resistance is related to mutations in the kinase domain of BCR-ABL1 gene in about one-third of the resistant patients (O'Brien et al, 2003; Jabbour et al, 2006; Soverini et al, 2006; Hehlmann et al, 2007) . Second-generation TKIs offer therapeutic alternatives for those patients (Bhamidipati et al, 2013) .
Nilotinib, an orally bioavailable selective BCR-ABL1 second-generation TKI, is 30-fold more potent than imatinib, as observed in preclinical models, and overcomes some imatinib resistant BCR-ABL1 mutations (Weisberg et al, 2006) . A phase 2, open-label study evaluated the efficacy and safety of 400 mg nilotinib administered orally twice daily to 280 patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP) after imatinib failure or intolerance (Kantarjian et al, 2007) . At 6 months, the rate of major cytogenetic response (MCyR) (Ph ≤ 35%) was 48%, with 31% complete cytogenetic response (CCyR) (Ph = 0%). The estimated survival at 12 months was 95%. Adverse events reported in this phase 2 study were mostly mild to moderate, and there was minimal cross-intolerance with imatinib (Kantarjian et al, 2007) ; the promising data from this phase 2 study supported the granting of market authorization for nilotinib.
The objective of the TARGET-RMC (Tasigna As secondline theRapy in Glivec-resistant or intolerant CML PC patiEnts in currenT practice-complete molecular response) study was to describe, in a real-life setting, the management of patients with CML-CP treated with nilotinib as secondline, and evaluate the cytogenetic and molecular response rates including undetectable disease with ≥10 000 ABL1 transcripts (uMR 4 ), and time to reach the response. The study also evaluated the safety and tolerance of nilotinib during the 24 months of follow-up.
Methods
The TARGET-RMC study was a prospective, observational, descriptive study. This large cohort of 150 patients with CML-CP was performed at 50 active sites with hospital-based haematologists in France. Patients were included from January 2011 to January 2014.
The study was conducted in accordance with the Declaration of Helsinki, Good Epidemiological Practice (GEP) Guidelines of April 2007, and European and French regulations and was approved by respective ethics committees and the French Data Protection Authority (Commission Nationale de l'Informatique et des Libert es, CNIL) prior to the start of the study. Written informed consent was obtained from the participating subjects prior to study entry.
Patient population
Eligible patients were included in the study if they were aged 18 years or older, were in CML-CP, and for whom a treatment with nilotinib was planned or prescribed for less than 3 months as second-line after imatinib, owing to the fact that nilotinib is indicated for adult patients resistant or intolerant to prior therapy that included imatinib (http://www.ema.eu ropa.eu/docs/en_GB/document_library/EPAR_-_Product_Inf ormation/human/000798/WC500034394.pdf). Exclusion criteria were: previous treatment with another second-generation TKI, treatment with nilotinib for more than 3 months, and disease in accelerated phase or blast crisis. Investigators were asked to include consecutive patients responding to inclusion/exclusion criteria. There was no log for screened nonenrolled patients.
Data collection
Patients were followed up over 24 months. Information collected by the physician at study entry and around 3, 6, 12, 18 and 24 months (M3, M6, M12, M18 and M24, respectively) using patient medical records. Given that the present study was observational, the prescription (dosage) or the change of study treatment, nilotinib, as well as the treatment duration and concomitant medications were left to the discretion of the haematologist according to patients' routine management. As per approved European Summary of Product Characteristics, nilotinib should be administered twice daily at a total daily dose of 800 mg, taken every 12 h without food (http://www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_-_Product_Information/human/000798/ WC500034394.pdf).
Assessments
At the time of design of this study, the primary endpoint was previously known as the "complete molecular response rate" (undetectable transcript with a sensitivity level ≥10 4 , later defined as uMR 4 ), around 18 months of treatment, confirmed by a subsequent polymerase chain reaction (PCR) test around 24 months. Following a conservative approach, only patients with uMR 4 at 18 months, with a confirmed result later, around 24 months, were considered as reaching the primary endpoint. Patients who prematurely discontinued the study were all counted as treatment failure, regardless of the reason. In 2013, the European Leukaemia Net (ELN) recommendations (Baccarani et al, 2013) , according to Cross et al (2012) highlighted that the term "complete molecular response" should be avoided and substituted with the term "molecularly undetectable leukaemia", with specification of the number of the control gene transcript copies; thus, in this publication we replaced the term "complete molecular response" used in the TARGET-RMC protocol to uMR 4 , i.e., undetectable molecular disease in cDNA with MR 4 sensitivity (≥10 000 ABL1 transcripts). The other evaluated responses included the rate of patients with no CCyR at study entry who subsequently obtained a CCyR during the study and the time needed to reach such response. Actually, as molecular biology testing was more frequently performed than cytogenetics, and since MR 2 is acknowledged to approximate CCyR ; National Comprehensive Cancer Network (NCCN), 2017), it was also decided, together with the study Scientific Committee that MR 2 would be used instead of CCyR to describe the results of the TARGET-RMC subgroups and responses. Other endpoints consisted of the rate of patients with a major molecular response (MMR, defined by an BCR-ABL1 transcript ≤0Á1%) around 18 months, time to obtain this MMR, relationship between early MMR (within the first 6 months of treatment) and achievement of uMR 4 . Moreover, the rate of patients progressing to an accelerated phase or a blast crisis and the discontinuation rate of nilotinib were evaluated.
Molecular response as second-line treatment was defined as follows: MR 2 , based on PCR testing BCR-ABL1/ABL1 ≤1%; MR 3 or MMR, based on PCR testing BCR-ABL1/ABL1 ≤0Á1%; deep molecular response (DMR), based on either detectable disease with PCR testing BCR-ABL1/ABL1 ≤0Á01% or undetectable disease in cDNA with ≥10 000 ABL1 transcripts; and uMR 4 , undetectable disease in cDNA with ≥10 000 ABL1 transcripts (Baccarani et al, 2009) . At the start of the study, BCR-ABL1 transcript levels were commonly expressed on the International Scale in France, as molecular standardization was extended to most laboratories. 
Safety assessments
Evaluation of nilotinib tolerance was based on the frequency of all AEs as well as serious adverse events (SAEs) reported by the patients and/or investigators during the study. SAEs were defined according to the International Conference on Harmonisation Guidelines. (ICH Steering Committee, 2003) The investigator determined whether the event was related to treatment.
Statistical considerations
In order to estimate an anticipated proportion of 10% patients with uMR 4 at 18 months confirmed after 2 years of follow-up, with a confidence interval (CI) of AE5%, 138 evaluable patients were needed. To account for an estimated 8% of study discontinuation or missing data, 150 patients had to be included in the study. The "Reference Population" used for the data analysis encompassed all patients included in the study and treated with nilotinib, with available information after baseline.
Data analysis was descriptive. Quantitative variables were described in terms of number and percentage of missing values, the number of observed values, minimum, maximum, median, interquartile range (IQR), mean and standard deviation (SD). Qualitative variables were described in terms of number and percentage of missing values, the number of observed values, absolute proportion and percentage by modality.
The uMR 4 rate was analysed including the whole treated population (patients who left the study prematurely were deemed as treatment failure); only patients who were lost to follow-up immediately after inclusion were excluded from the study analysis. Analyses were also performed on predefined subgroups, by age (< or ≥65 years), treatment duration with imatinib (> or ≤18 months), reason for discontinuation of imatinib (lack of efficacy, intolerance or both), transcript levels at inclusion (patients with or without MR 2 , MMR and DMR (MR 4 or deeper, detectable or undetectable), and the initial daily dose of nilotinib (800, 600 or <600 mg/day). The Statistical Analysis System (SAS), version 9.2 (SAS Institute Inc, Cary, NC, USA), was used for all analyses.
Results
Overall, 150 patients were included in this observational cohort study, among whom four patients were excluded; two were untreated and two for lack of information after baseline. Thus, a total of 146 were analysed (Reference Population). Patients evaluable for the primary endpoint without major protocol deviation (n = 141) constituted the Per-Protocol (PP) Population (Fig 1) . In the reference population, 53 patients (36Á3%) prematurely terminated the study, essentially due to nilotinib treatment discontinuation (43 patients; 29Á5%), which was motivated by treatment inefficacy in 10 patients (6Á8%), treatment intolerance in 27 patients (18Á5%) and other reasons in 6 patients (4Á1%) (Fig 1) . The median (IQR) age of the patients was 61 (47-68) years, with a sex ratio (male/female) of 1Á35. The median (IQR) time from diagnosis of CML to inclusion in the study was 26 (13-68) months (Table I) . Two-thirds of patients were treated with imatinib for more than 18 months and almost two-thirds of patients have stopped imatinib treatment due to lack of efficacy (Table I) .
At study entry, 84Á9% of patients had a complete haematological response, 59Á6% a molecular response MR 2 (considered as CCyR), 28Á8% a major molecular response (MMR) and 11Á6% a DMR; none of the patients (n = 17) with DMR at baseline had started nilotinib before study inclusion (Table II) . Moreover, 61Á0% of patients started treatment with nilotinib at an initial dose of 800 mg/day, 29Á5% at 600 mg/day and 9Á6% at a dose of <600 mg/day. The median dose of nilotinib was 800 mg/day in the first 6 months then 600 mg/day until study end. As planned in the protocol, the majority of patients (135/146) started nilotinib treatment close to the enrolment date in the study; only 9 patients had started nilotinib between 1-30 days before inclusion, and 2 patients received nilotinib more than 1 month before starting the study (Table I ). The median [IQR] time from study inclusion to nilotinib treatment start was 1Á0 day (0Á0-3Á0). The median (IQR) nilotinib treatment duration was 23Á7 (15Á9-24Á8) months for all the patients and 10Á1 (2Á8-18Á7) months for the 46 patients who discontinued the Patient disposition. *All 5 patients were included in the reference population for safety and efficacy analysis. **Discontinued study before the third month (M3) for protocol deviation. ***1 patient discontinued nilotinib due to intolerance, the other completed the 24-month study. M, months; N, number of patients in bar graphs. treatment prematurely (n = 43) or died (n = 3). This duration was roughly similar across all predefined subgroups. In total, 25 patients (17Á1%) had at least one temporary discontinuation of nilotinib treatment for a median duration of 13Á5 days.
Regarding the cytogenetic profile, the proportion of patients having a cytogenetic profile were 14Á0% (20/143) at M3, 11Á6% (15/129) at M6, 15Á3% (19/124) at M12, 8Á9% (10/112) at M18 and 5Á0% (5/101) at M24. The molecular profile was analysed in all the patients at study entry and the majority of patients underwent molecular analysis between M6 (114/129 patients; 88Á4%) and M24 (94/101; 93Á1%); a lower rate was observed at M3 (111/143; 77Á6%). Predefined sensitivity analyses were conducted in 3 populations of patients: the PP Population (n = 141), patients who were evaluated at 18 months (n = 104), and patients evaluated at 18 and 24 months (n = 94). These sensitivity analyses showed comparable results to the primary analysis conducted on the Reference Population, with respective rates of uMR 4 of 11Á3% (95% CI: 6Á6-17Á8), 15Á2% (95% CI: 9Á0-
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23Á6) and 17Á8% (95% CI: 10Á5-27Á3).
Other responses. Molecular responses at study entry and during the study as well as time to response are summarized in Table III (Table III) . CCyR reported within 3 months prior to inclusion, n/n analysed (%) 24/59 (40Á7)
Nilotinib started in patients, n (%) Just after study entry (planned treatment with nilotinib)
(92Á5)
Within 30 days prior to study entry 9 (6Á2) More than 30 days prior to study entry 2 (1Á4) Patients with a nilotinib starting dose of 800 mg/600 mg/<600 mg (%) 61/29Á5/9Á5 % calculated as n/N, unless otherwise specified; CCyR, cytogenetic complete response; CML, chronic myeloid leukaemia; Q, quartile. *Excluded from per protocol population. In addition, the rate of uMR 4 was higher among patients with early MMR, defined as MMR reached in the first 6 months of treatment with nilotinib (11/37 patients; 29Á7%), as compared to those not having an early MMR (4/67; 6Á0%), (P = 0Á0023). There were no other noticeable differences between the predefined subgroups. Table II describes the molecular response rates observed at inclusion and at each visit. The distribution of the total number of patients with documented molecular profiles according to the transcript BCR-ABL1/ABL1 ratio at each study visit (inclusion, M3, M6, M12, M18, M24) is illustrated in Fig 2. During treatment with nilotinib, only one patient progressed to accelerated phase, 1Á9 months after initiation of nilotinib, and no progression to blast crisis was observed.
Safety
A total of 119/146 patients (81Á5%) reported at least one AE. This corresponded to 574 reported AEs, of which 111 were SAEs. Grade 3 AEs were reported in 45 patients (30Á8%) and 3 patients (2Á1%) had Grade 4 AEs. Thirty patients (20Á5%) reported at least a nilotinib-related SAE. There was no notable difference observed in the whole incidence of AEs with respect to age, starting dose of nilotinib, and imatinib discontinuation for intolerance or inefficacy. An increased tendency of SAEs in patients treated with an initial dose of nilotinib 800 mg/day was observed compared to patients on initial dose of 600 mg/day.
The most frequent (≥10% of patients) extra-haematological Treatment Emergent Adverse Events (TEAEs) that were considered to be related to treatment with nilotinib were pruritus (16Á4%), asthaenia (13Á7%) and dry skin (13Á0%). TEAEs related or not to treatment with nilotinib observed in ≥5% of patients are summarized in Table SI . Nilotinib treatmentrelated diabetes mellitus was reported in four patients (2Á7%) and was assessed as a SAE in three of those patients (2Á1%).
Ischaemic cardiovascular TEAEs were reported in 18 patients (12Á3%) and are summarized in Table IV . The distribution of these ischaemic cardiovascular TEAEs was similar between the predefined subgroups, except for patients aged ≥65 years who had a higher incidence (8/59 patients; 13Á6%) compared with those <65 years of age (5/87; 5Á7%).
Haematological toxicity related to treatment with nilotinib was observed in four patients and was poorly documented: cytopenia (one patient), neutropenia (one patient), thrombocytopenia (one patient), anaemia (two patients) and unspecified haemotoxicity (one patient).
Grade 3/4 AEs, related or not to nilotinib treatment, were observed in ≥1% of patients and are summarized in Table SII. Three patients died during the study: one from sudden death with cardiac arrest, 8 days after starting treatment with nilotinib (not proven but may be related to cardiac rhythm abnormalities), the second following a cerebrovascular stroke which occurred 15 months after the start of treatment, and the third after acute lower limb ischaemia which occurred 19 months after the start of treatment. A fourth patient died 4 months after stopping nilotinib treatment, following aggravation of a grade 4 amyotrophy; this was considered to be the consequence of a lower limb ischaemia that was aggravated during the nilotinib treatment period.
Inefficacy of the drug was reported as an AE in 10 patients (6Á8%). A total of 27 patients (18Á5%) discontinued the study due to nilotinib intolerance. 
Discussion
The TARGET-RMC study allowed the observation, in a reallife setting, of a large cohort of patients with CML-CP for whom treatment with nilotinib was prescribed as second-line therapy after imatinib, with a follow-up of 24 months. In the IRIS study, after a median follow-up of 11 years, nearly half of patients stopped imatinib (49Á2%), all causes taken together . Our study confirms the known reasons for switching from first-line imatinib to second-line/second-generation TKI (2G-TKI) treatment, with approximately two-third of the patients switching for inefficacy and one-third for intolerance. It also confirms the efficacy of nilotinib in this setting in routine clinical practice, as demonstrated in previous clinical trials (Kantarjian et al, 2011; Nicolini et al, 2012) . In addition, it provides information on molecular response rates and response kinetics that were not documented in those previous trials. Finally, the safety observed during the study was in line with the known safety profile of nilotinib (http://www.e ma.europa.eu/docs/en_GB/document_library/EPAR_-_Produc t_Information/human/000798/WC500034394.pdf), and no new signal was detected. The median age of patients in TARGET-RMC was similar to those in a recent CML-CP French cross-sectional epidemiological survey (62 years) (Etienne et al, 2016) and were older than those in other second line nilotinib clinical studies (Kantarjian et al, 2011; Nicolini et al, 2012; Hughes et al, 2014; Gora-Tybor et al, 2015; Kuo et al, 2015; Rea et al, 2015; Miyamura et al, 2016) .
At the time of TARGET-RMC protocol design, the term "complete molecular response" was used, and the definition included undetectable BCR-ABL1 transcript with at least 10000 ABL1 copies, according to ELN 2009 definitions (Baccarani et al, 2009 ). Due to evidence that leukaemic stem cells persisted even in patients without any BCR-ABL1 signal in PCR (Ross et al, 2010; Chomel et al, 2011) , the 2013 revised ELN recommendations (Baccarani et al, 2013) highlighted that the term "complete molecular response" should be avoided and substituted with the term "molecularly undetectable leukaemia", with specification of the number of the control gene transcript copies, according to Cross et al (2012) . In TARGET-RMC publication, we replaced the term "complete molecular response" used in the initial protocol by "undetectable molecular disease in cDNA with MR 4 sensitivity (≥10 000 ABL1 transcripts) (uMR 4 ).
The proportion of patients who achieved the primary endpoint, confirmed uMR 4 at 18 and 24 months, was consistent with the study hypothesis. This proportion was, as expected, higher in patients who had stopped imatinib treatment due to intolerance than those who stopped imatinib due to inefficacy. Higher rates of confirmed uMR 4 were also observed in patients with MMR at baseline compared with patients without MMR. Of patients without DMR at study entry, 44Á2% achieved DMR within a median time of 6Á24 months in TARGET-RMC. Of patients with MR 2 (equivalent to CCyR) at study entry, 51Á4% achieved DMR within a median time of 5Á67 months. According to ELN recommendations (Baccarani et al, 2013) , optimal response to second-line therapy at 12 months in case of imatinib failure is MR 2 (BCR-ABL1/ABL1 <1%) and/or CCyR and, at any time, MMR (BCR-ABL1/ABL1 ≤0Á1%). In the present study, the MMR rate was higher (66Á3%) and more quickly achieved (median time 5Á7 months) compared with the results in heavily pre-treated patients of the ENACT (Expanding Nilotinib Access in Clinical Trials) study, in which 37% of the French subset of patients (n = 168) achieved a MMR by 12 months (Nicolini et al, 2012) . Nilotinib was approved for second-line treatment after imatinib-resistance or -intolerance on the basis of the initial results of a phase 2 open-label study (Kantarjian et al, 2007) . In the 24-month follow-up analysis (Kantarjian et al, 2011) , CCyR was achieved in 51% of imatinib-intolerant and 41% of imatinib-resistant patients (enrolment of imatinib-intolerant patients in MCyR or better at study entry was not permitted, resulting in the imatinib-intolerant population having disease characteristics more closely resembling imatinib resistance). The recent French epidemiological survey in unselected patients with CML-CP (Etienne et al, 2016) showed that the cytogenetic response was less investigated than the molecular response. On the other hand, ELN guidelines (Baccarani et al, 2013) indicate that the possibility of using a molecular test alone is sufficient to evaluate response to treatment after CCyR and MMR achievement. (Cortes et al, 2016a) . Due to the strong association between molecularresponse (MR) milestones and long-term treatment outcomes, molecular results now guide clinical decision-making and play an essential role in the clinical management of CML patients National National Comprehensive Cancer Network (NCCN, 2017) . The safety profile of nilotinib evolved after the first market authorization with recommendations to assess and monitor lipid profiles, blood glucose levels and cardiovascular risk factors before and during treatment with nilotinib which appeared in August 2013 , February 2014 and May 2014 In the present observational study, ischaemic cardiovascular TEAEs were reported in 18 patients and, as expected, occurred more frequently in older patients. In the LASOR study (Cortes et al, 2016a) , five patients in the nilotinib group versus none in the imatinib group had cardiovascular events during the study. No incidence of peripheral arterial occlusive disorder was reported in the NOVEL (Nilotinib in patients with CP or AP Philadelphia chrOmosome positiVe (Ph+) chronic myElogenous Leukaemia) study (Kuo et al, 2015) which enrolled patients younger (median age of 47 years) than those in TARGET-RMC.
The safety profile of nilotinib presented in the TARGET-RMC study population complies with its known safety profile observed in other cohorts of patients switching from imatinib (Nicolini et al, 2012; Hughes et al, 2014; Cortes et al, 2016a,b; Miyamura et al, 2016) .
The proportion of patients who discontinued nilotinib treatment due to AEs or drug-related toxicity has been reported to range from 4Á7% to 19% (Kantarjian et al, 2011; Nicolini et al, 2012; Kuo et al, 2015; Cortes et al, 2016a,b) . Study discontinuation motivated by treatment inefficacy was low (10 patients; 6Á8%), compared to treatment intolerance (27 patients; 18Á5%) in the TARGET-RMC study. No pattern was noted regarding nilotinib treatment-discontinuation based on inefficacy or intolerance across nilotinib studies.
The approved daily dose of nilotinib in second-line treatment is 800 mg. In the present study, 61% of patients initiated treatment at this recommended dose, and at the end of study, the median dose was 600 mg/day. Of note, the indication of nilotinib in first line treatment was approved in 2011 based on a total daily dose of 600 mg. In addition, and to our knowledge, there are only two recent studies documenting results with a 600 mg/day dose of nilotinib post-imatinib treatment: the ENRICH study (Cortes et al, 2016b) and the ENESTPath study (Rea et al, 2015) , neither of which included imatinib-resistant patients.
This study has some limitations inherent to its observational non-interventional nature, particularly the absence of a comparator arm, and no centralized molecular response analyses. On the other hand, there was no log for screened nonenrolled patients and the enrolment period for patients was relatively long, which may affect the homogeneity of the data in a growing therapeutic area; however, this may be inevitable in a rare disease such as CML with a high number of competitive clinical trials. These limitations are balanced with a relatively low amount of missing data, probably related to a clinically adequate study design and monitoring, which could minimize bias in the analysis. Finally, the change in clinical practice and monitoring recommendations (Baccarani et al, 2013) , driven by the possibility of using a molecular test alone as sufficient to evaluate response to treatment, yielded less frequent performance of cytogenetic tests, which limited the analysis of the cytogenetic responses in the present study and consequently the indirect comparison to the main endpoints of the pivotal study. This practice was emphasized by the molecular standardization of local laboratories and reimbursement policy in France. In summary, the French nationwide large cohort TAR-GET-RMC study adds valuable information to the body of evidence on the efficiency of nilotinib in the treatment of patients with CML in chronic phase, for whom treatment with imatinib was stopped due to lack of efficacy or intolerance. Real-life data in patients with CML-CP who receive nilotinib as first line treatment are currently under investigation in another ongoing observational study.
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